Vivesto AB
OASMY
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.61K
Close$
$0.00
1300% upside
Current Fair Value
1300% upsideUndervalued by 1300% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20,606.00 |
|---|---|
| Enterprise Value | $-948,394.00 |
| Dividend Yield | $0.00 (-) |
| Earnings per Share | $-0.48 |
| Beta | 0.82 |
| Outstanding Shares | 0 |
Return
| Return on Equity | -14.60% |
|---|---|
| Return on Assets | -13.67% |
| Return on Invested Capital | -19.47% |
Valuation & Multiples
| P/E Ratio | -217.93 |
|---|---|
| PEG | 1294.8 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.03 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$169,232
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Vivesto AB
4 employees
CEO: Mr. Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D. Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products port...